Balloon Valvuloplasty Devices Market Report

To learn more about this report, Download Free Sample Report

Global Balloon Valvuloplasty Devices Market Size

The global balloon valvuloplasty devices market size was valued at USD 2505.18 million in 2025 and is anticipated to reach USD 2617.91 million in 2026 from USD 3722.93 million by 2034, growing at a CAGR of 4.5% during the forecast period from 2026 to 2034.

The Balloon aortic valvuloplasty (BAV) devices are characterized by a sustained upward trend in procedures performed worldwide, despite the emergence of transcatheter aortic valve replacement (TAVR) as a prominent alternative treatment option. BAV remains a standard procedure due to its effectiveness in improving hemodynamics and clinical status, particularly as a prominent therapy for aortic valve replacement (AVR) or noncardiac surgery. With low rates of procedural mortality, stroke, and vascular complications, BAV is considered a safe intervention. Recent advancements in BAV techniques, including alternative access sites, balloon catheters, and lithotripsy, have expanded their applicability to broader patient populations and contributed to improved complication rates.

MARKET DRIVERS

The Balloon Valvuloplasty Devices Market is witnessing significant growth driven by various factors.

Firstly, the increasing prevalence of valvular heart diseases, such as aortic stenosis and mitral regurgitation, significantly contributes to the market growth. As these conditions become more prevalent, there is a growing need for effective treatment options, increasing the demand for minimally invasive procedures like balloon valvuloplasty.

Secondly, continuous advancements in balloon technology are pivotal in expanding the market.

Innovations in materials, designs, and delivery systems enhance the safety and efficacy of balloon valvuloplasty procedures, making them more attractive to healthcare providers and patients. These advancements improve patient outcomes and drive adoption rates in medical professionals. All these factors are enhancing the growth of the global market share. Moreover, other factors, such as the aging population with heart diseases, contribute to the market's growth. With the global population aging, the incidence of valvular diseases tends to increase, further fueling the demand for treatment options like balloon valvuloplasty. Additionally, the preference for minimally invasive procedures continues to rise due to factors like shorter recovery times and reduced risks compared to traditional open-heart surgeries fuels the market revenue globally. 

Furthermore, efforts to raise awareness about valvular heart disorders and favorable clinical evidence and regulatory support are bolstering market expansion.

With the increasing healthcare infrastructure, especially in emerging markets, access to advanced medical treatments like balloon valvuloplasty has become more widespread, driving demand for the devices by propelling the market value. These combined factors drive significant growth in the balloon valvuloplasty device market, with promising prospects in the forecast period.

Advancements in balloon aortic valvuloplasty (BAV) techniques, particularly exploring alternative access sites such as brachial and radial arteries, present significant opportunities for the balloon valvuloplasty device market. With a growing emphasis on minimizing risks associated with femoral access, the development of devices compatible with brachial and radial approaches can expand the applicability of BAV to a broader patient population, including those with peripheral artery disease (PAD). 

The introduction of novel technologies like intravascular lithotripsy (IVL) for vascular access in calcified PAD patients not only facilitates the safe passage of large bore sheaths for transcatheter aortic valve replacement (TAVR) procedures but also opens avenues for applications in BAV. The expected prevalence of heart diseases in the upcoming years is expected to augment the market growth during the forecast period.

MARKET RESTRAINTS

Major significant restraints in the balloon valvuloplasty device market arise from the declining incidence of rheumatic heart disease, particularly in industrialized nations.

As rheumatic mitral stenosis remains a primary indication for balloon valvuloplasty, the decreasing prevalence of this condition limits the patient pool eligible for the procedure by limiting the market expansion. Additionally, the trend toward a decline in percutaneous mitral balloon valvuloplasty (PMV) procedures, as evidenced by reduced utilization rates over the years, presents a challenge for market growth. This decline may be attributed to several factors, including advancements in transcatheter mitral valve replacement (TMVR) techniques and technologies, which offer alternative treatment options for patients and are expected to hamper market growth.

The major challenge facing the balloon valvuloplasty device market is the evolving patient demographics presenting for PMV procedures. With an increasing number of older populations and those with less favourable mitral valve anatomical features undergoing PMV, there is a heightened risk of procedural complications and adverse outcomes. Additionally, the emergence of TMVR as a potential alternative for patients with severe mitral annular calcification (MAC) presents a challenge for the balloon valvuloplasty device market. While TMVR offers a less invasive option for high-risk patients, challenges related to device complexity, anatomical considerations, and procedural outcomes must be addressed to optimize its role in mitral valve disease management and impact the market dynamics of balloon valvuloplasty devices.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Size Insights

The 23mm segment held the most significant global market share in 2025. These devices treat stenotic heart valves by widening the narrow opening, improving blood flow. The high effectiveness of the device is gaining traction among people, boosting the segment's growth. 

The 29mm segment is estimated to have prominent growth with CAGR during the forecast period. These are specially designed for patients requiring larger balloons to dilate their stenotic heart valves. The other segment is expected to grow steadily during the forecast period due to the design and materials used in the balloon catheter, which make it easy to navigate through the vasculature. 

By Type Insights

The aortic valvuloplasty segment accounted for a significant market share in the global balloon valvuloplasty market revenue. Increasing product launches associated with stenosis treatment and various strategic initiatives by the market players are propelling segment growth. The growing cases of valvular heart diseases are enhancing the segment growth by raising the global market revenue. 

The pulmonary valvuloplasty segment is estimated to maintain steady growth during the forecast period. 

By End-User Insights

The hospital segment dominated, enhancing the segment growth due to patients' high preferences.

REGIONAL ANALYSIS

North American region accounted for the most significant global balloon valvuloplasty market share in 2023. The growing older population and the rising prevalence of valvular heart diseases drive the market growth. The presence of prominent market players in the region and advanced surgical procedures with effective treatment fuel the growth of the market revenue. Increasing innovative procedures for developing medical devices and continuous product launches and approvals propel regional market expansion. For instance, Medtronic, a leading medical technology company, launched its Adapta Balloon Expander catheter in 2021 to treat aortic stenosis. According to data published by the Centers for Disease Control and Prevention, around 2.5% of the population suffers from valvular heart disease in the U.S., which raises the adoption of balloon valvuloplasty procedures in the region. 

Asia Pacific region is projected to have the fastest growth during the forecast period due to growing heart diseases, especially valvular heart diseases the rapid approvals from the Chinese government are positively impacting the market growth. Increasing the establishment of top market player companies in the region fuels regional market growth. The growing advancements in the healthcare industry in countries like China, Japan, and India are driving market growth. The increasing medical tourism industry in Asia Pacific countries, which is raising the number of procedures in the region, enhances the expansion of the market. 

KEY MARKET PLAYERS

Some of the key market players in the balloon valvuloplasty devices market include

• Medtronic plc.
• Terumo Corporation
• Boston Scientific Corporation
• Abbott Laboratories Ltd.
• Edwards Lifesciences
• BVM Medical Ltd.
• Toray Industries Inc.
• Palex Medical

RECENT MARKET HAPPENINGS

• In March 2021, Keystone Heart Ltd., a medical device manufacturer, announced an exclusive distribution agreement with Intervalve Medical, Inc. to sell and market their balloon aortic valvuloplasty products in the U.S.

MARKET SEGMENTATION

This research report on the global balloon valvuloplasty devices market has been segmented and sub-segmented based on size, type, end-user, and region.

By Size

• 23mm
• 26mm
• 29mm

By Type

• Aortic Valvuloplasty 
• Pulmonary Valvuloplasty 

By End-User

• Hospitals 
• Ambulatory Surgical Centers 
• Others 

By Region

• North America
• Europe
• Asia Pacific 
• Latin America 
• Middle East and Africa